CAR-T in the Courts – Genetic Engineering & Biotechnology News
|
CAR–T in the Courts
Genetic Engineering & Biotechnology News A patent fight continues over engineered chimeric antigen receptors for T–cell therapies (CAR-T). In December 2016, the Patent Trial and Appeal Board upheld a patent for a specific design of a chimeric antigen receptor (CAR) designed by researchers at … |
|
Alternative Immunotherapy Drug More Effective than Current Standard of Care in Treating Advanced Melanoma after …
Newswise (press release) Newswise — The immunotherapy drug nivolumab is safer and more effective than ipilimumab—the current standard of care—in treating patients with resected stage III and stage IV melanoma, according to an international clinical trial led by a researcher … |
Targeted Oncology |
PFS Benefit in NSCLC Immunotherapy Predicted With Liquid Biopsy for Mutation Burden
Targeted Oncology Tumor mutation burden in blood (bTMB) ≥16 had a significant association with improved progression-free survival (PFS) in patients treated with the PD-L1 inhibitor atezolizumab (Tecentriq), according to findings reported at the 2017 ESMO Congress. |
|
Alternative Immunotherapy Drug More Effective than Current Standard of Care in Treating Advanced Melanoma after …
Markets Insider NEW YORK, Sept. 10, 2017 /PRNewswire-USNewswire/ — The immunotherapy drug nivolumab is safer and more effective than ipilimumab—the current standard of care—in treating patients with resected stage III and stage IV melanoma, according to an … |